Roman seems a typical six-year-old boy, smiling shyly next to his younger sister and mother, Silvia, as they open the door to their Amsterdam home.
However, Roman has Duchenne muscular dystrophy (DMD), a genetic disorder that already makes it hard to walk long distances and will probably put him in a wheelchair by his teens. Lung and heart problems mean most DMD patients die aged 25 to 30 years.
“He knows that his muscles are not that strong, but he does not know it is progressive,” Dutch events manager Silvia says. “He will ask about it himself, when he can handle it. That’s the hard thing, his pain — that’s the hardest thing.”
Photo: REUTERS
Yet there is a glimmer of hope. Roman’s mother believes a small Dutch biotech company called Prosensa, located 40km away in the university town of Leiden, may finally have found a way to help Roman and others like him.
She’s not the only excited one. GlaxoSmithKline is throwing its weight behind the new drug and the two companies last month started a final-stage Phase III clinical study of a product that might help up to 13 percent of boys with DMD.
Silvia hopes Roman will be enrolled in subsequent trials.
Prosensa is one of a new wave of successful European biotechs, many of them in the Benelux countries and Scandinavia. They are stepping over a past generation of biotech failures and starting to win interest from investors.
Significantly, it focuses on rare diseases — a red-hot area in the wake of Sanofi-Aventis’s US$20 billion-plus deal to buy Genzyme.
Europe’s biotech sector has stumbled in the past, but there is now renewed talk of stock market listings and trade sales.
Prosensa is preparing the ground for an initial public offering (IPO) and will choose its moment carefully.
“It is one of the options,” chief executive Hans Schikan said.
Prosensa last year hired a chief financial officer with IPO experience, although chief business officer Luc Dochez stresses a flotation “will be a choice, not a forced option” as Prosensa still has two years of funding.
Other young biotech companies are also eyeing the public markets, including Dutch rival Kiadis, a specialist in cell-based therapy, which bankers believe is again looking to list after pulling a planned IPO in 2007.
There are signs the market is recovering from recent trough years and this year could see more IPOs, with investor interest in places like Amsterdam and Brussels encouraging, although the overall picture is fragile.
“The market is improving. In Europe, a few biotech IPOs are being planned,” one banker said.
The Netherlands and Belgium are a hotspot, helped by the sentiment-boosting US$2.4 billion buyout of Dutch vaccine maker Crucell by Johnson & Johnson and high hopes for Belgian biotech star performer ThromboGenics. Some German and Austrian IPOs are also on the cards, bankers say.
BRITISH BLUES
Nomura analyst Samir Devani detects a “power shift” in European biotech, particularly away from the UK, where a series of blow-ups with key pipeline products at companies like Antisoma have taken a heavy toll on confidence.
Last year saw the emergence of a new group of well-financed European biotechs worth US$500 million or more, including ThromboGenics, Sweden’s Medivir, Denmark’s Bavarian Nordic, Sweden’s Diamyd Medical and Norway’s Algeta, he said.
The biotech casino remains high-risk, given the binary nature of the clinical trials that drive values. However, the growing appetite of “Big Pharma” for biotech assets is underpinning the sector and analysts at Jefferies expect out-licensing deals and consolidation to remain key share price drivers this year.
For those companies braving the IPO market, however, the waters are still choppy.
Danish biotech Zealand Pharma, for example, got its issue away in November, but only after pricing it at the low end of the indicated range. The shares have fallen more than 20 percent since then.
More recently, Swiss-Italian biotech Philogen scrapped its plans to list in Milan after Bayer ended a partnership with the group.
Despite the setbacks, Thomson Reuters data shows an overall pick-up in biotech IPOs last year after a dramatic slowdown in 2008 and 2009.
US biotech have also had mixed results this year, with Pacira Pharmaceuticals and Endocyte Inc going public, but Clarus Therapeutics pulling its IPO on Feb. 11.
Anne Portwich, a partner at Life Sciences Partners, said many venture capitalists looking to realize biotech investment gains were now more focused on M&A than IPOs.
“Companies that want an IPO have to be much more mature than they did in the past,” she said.
BENELUX VS SWITZERLAND
After various high-profile setbacks, times are tough in Switzerland. Historically a center of excellence, the talk these days among biotech executives is of survival.
Sander Slootweg, managing partner at venture capital firm Forbion, said that in the past, some over-priced Swiss biotechs had raised cash at “valuations that we would never invest in.”
Tim Dyer, chief financial officer of Swiss biotech Addex, said a shortage of capital may mean some companies either have to close or merge to create critical mass.
“One of the strategies of these sub-SF$100 million [US$107.7 million] market cap biotechs could be to combine with other similarly sized companies to recreate the critical mass and put themselves back on the radar screen of larger funds,” Dyer said.
Vontobel analyst Andrew Weiss agreed a wave of M&A could be brewing as a last resort for some companies.
For different reasons, he said Cytos Biotechnology, Cosmo Pharmaceuticals, Evolva and also Addex could also look to team up, but not necessarily with each other.
Back in Belgium, Edwin Moses, the CEO of biotech Ablynx, which makes drugs based on llama DNA, finds the investor mood rather different — helped by a strong retail interest that runs beyond the -traditional wary Belgian dentist.
“I’ve found that people in the street, bakers and taxi drivers, they all follow companies like Ablynx, like ThromboGenics, very carefully in a way that I’ve not experienced in the larger countries,” Moses said.
“There’s quite a sophisticated retail market here where people pay attention even to complicated stories,” he said. “At the moment the place to be seems to be here.”
Whether the science will help boys like Roman remains to be seen. Prosensa and Glaxo are still recruiting the 180 patients they need for their key Phase III study and it will take 48 weeks of regular injections to determine if they really do have the first treatment to alter the course of DMD.
“Hope gives life,” said Roman’s mother, Silvia.
purpose: Tesla’s CEO sought to meet senior Chinese officials to discuss the rollout of its ‘full self-driving’ software in China and approval to transfer data they had collected Tesla Inc CEO Elon Musk arrived in Beijing yesterday on an unannounced visit, where he is expected to meet senior officials to discuss the rollout of "full self-driving" (FSD) software and permission to transfer data overseas, according to a person with knowledge of the matter. Chinese state media reported that he met Premier Li Qiang (李強) in Beijing, during which Li told Musk that Tesla's development in China could be regarded as a successful example of US-China economic and trade cooperation. Musk confirmed his meeting with the premier yesterday with a post on social media platform X. "Honored to meet with Premier Li
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Dutch brewing company Heineken NV on Friday announced an investment of NT$13.5 billion (US$414.62 million) over the next five years in Taiwan. The first multinational brewing company to operate in Taiwan, Heineken made the statement at a ceremony held at its brewery in Pingtung County. It also outlined its efforts to make the brewery “net zero” by 2030. Heineken has been in the Taiwanese market for 20 years, Heineken Taiwan managing director Jeff Wu (吳建甫) said. With strong support from local consumers, the Dutch brewery decided to transition from sales to manufacturing in the country, Wu said. Heineken assumed majority ownership and management rights
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI